-
Advertorial
-
FOCUS
-
Guide
-
Lifestyle
-
Tech and Vogue
-
TechandScience
-
CHTF Special
-
Nanhan
-
Futian Today
-
Hit Bravo
-
Special Report
-
Junior Journalist Program
-
World Economy
-
Opinion
-
Diversions
-
Hotels
-
Movies
-
People
-
Person of the week
-
Weekend
-
Photo Highlights
-
Currency Focus
-
Kaleidoscope
-
Tech and Science
-
News Picks
-
Yes Teens
-
Fun
-
Budding Writers
-
Campus
-
Glamour
-
News
-
Digital Paper
-
Food drink
-
Majors_Forum
-
Speak Shenzhen
-
Business_Markets
-
Shopping
-
Travel
-
Restaurants
-
Hotels
-
Investment
-
Yearend Review
-
In depth
-
Leisure Highlights
-
Sports
-
World
-
QINGDAO TODAY
-
Entertainment
-
Business
-
Markets
-
Culture
-
China
-
Shenzhen
-
Important news
在线翻译:
szdaily -> China
Cancer researcher shares Sjoberg Prize of Sweden
    2018-February-7  08:53    Shenzhen Daily

CHINA’S cancer researcher Zhu Chen won the Sjoberg Prize 2018, together with French researchers Anne Dejean and Hugues de The, for the unique treatment that cures a once fatal cancer, announced the Royal Swedish Academy of Sciences on Monday night.

According to a statement from the Royal Swedish Academy of Sciences, the prize was awarded to them “for the clarification of molecular mechanisms and the development of a revolutionary treatment for acute promyelocytic leukaemia.”

This year’s Sjoberg laureates have developed a new and targeted treatment for a specific form of blood cancer called acute promyelocytic leukemia. It was once one of the deadliest forms of cancer, but it is now possible to cure nine out of 10 patients who receive the new treatment, the release reads.

The treatment is unique because it is the first standard treatment for acute leukaemia that does not include chemotherapy. Instead, a combination treatment is used, which consists of a form of vitamin A, “all-trans retinoic acid,” also called ATRA, along with arsenic trioxide.

The use of arsenic comes from traditional medicine, and has been scientifically tested and proven to be effective when used in this way. The laureates have made this revolutionary development possible by methodically mapping the molecular mechanisms responsible for the disease.

By identifying a specific genetic mutation and aiding the destruction of a faulty protein in specific cells, it was possible to stop the process that resulted in death for three out of four patients. This treatment means the cancer cells disappear because they lose the ability to renew themselves.

These discoveries have been made in stages since the 1980s, and the treatment’s effectiveness has been confirmed in numerous scientific studies. In many countries, this treatment combination is now the first choice for treating acute promyelocytic leukaemia.

“This prize means not only glory, but even more importantly a responsibility for me, my team and our collaborators to continue efforts in the understanding of disease mechanisms of other types of hematological malignancies and to develop innovative, effective therapeutic strategies against those diseases through collaboration with other partners,” Chen said.

Chen, born in 1953 in China, is now professor at prestigious Shanghai Jiao Tong University. Anne Dejean, born in 1957 in France, is professor at Institut Pasteur, France. Hugues de The, born in 1959 in France, is professor at College de France, France.

The prize is an annual international prize in cancer research, amounting to US$1 million, of which US$100,000 is the prize sum and US$900,000 is funding for future research.

(Xinhua)

 

深圳报业集团版权所有, 未经授权禁止复制; Copyright 2010, All Rights Reserved.
Shenzhen Daily E-mail:szdaily@szszd.com.cn